Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models

BACKGROUND: Glioblastoma highly expresses the proto-oncogene MET in the setting of resistance to bevacizumab. MET engagement by hepatocyte growth factor (HGF) results in receptor dimerization and autophosphorylation mediating tumor growth, invasion, and metastasis. Evasive revascularization and the...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Piao, Yuji, Park, Soon Young, Henry, Verlene, Smith, Bryan D., Tiao, Ningyi, Flynn, Daniel L., de Groot, John F.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2016
Matèries:
Basic and Translational Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4998992/
https://ncbi.nlm.nih.gov/pubmed/26965451
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now030
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars